Citius Oncology Stock Performance
| CTOR Stock | 1.11 0.04 3.48% |
The firm shows a Beta (market volatility) of 0.59, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Citius Oncology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Citius Oncology is expected to be smaller as well. At this point, Citius Oncology has a negative expected return of -0.21%. Please make sure to confirm Citius Oncology's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Citius Oncology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Citius Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Even with uncertain performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in March 2026. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
1 | How Citius Oncology Inc. stock reacts to oil prices - Price Action Weekly Market Pulse Alerts - newser.com | 11/14/2025 |
2 | Will Citius Oncology Inc. stock deliver strong dividend growth - 2025 Volatility Report Community Shared Stock Ideas - newser.com | 11/17/2025 |
3 | Citius Oncology to Exhibit LYMPHIR for CTCL Patients at ASH 2025 - Stock Titan | 11/25/2025 |
4 | Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim | 12/04/2025 |
5 | Citius Oncology Announces Closing of 18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules | 12/10/2025 |
6 | Citius Pharmaceuticals Surges 22 percent After Hours Heres Why | 12/24/2025 |
7 | Aug Sectors Why Citius Oncology Inc. stock attracts global investors - Trade Analysis Report Weekly Watchlist of Top Performers - ulpravda.ru | 01/08/2026 |
8 | Citius Oncology, Inc. Is Breakeven Near | 01/13/2026 |
9 | CEO Moves Why is Citius Oncology Inc stock going down - 2025 Trading Recap Smart Investment Allocation Insights - baoquankhu1.vn | 01/26/2026 |
| Begin Period Cash Flow | 112.00 | |
| Total Cashflows From Investing Activities | -5.8 M |
Citius Oncology Relative Risk vs. Return Landscape
If you would invest 143.00 in Citius Oncology on November 9, 2025 and sell it today you would lose (32.00) from holding Citius Oncology or give up 22.38% of portfolio value over 90 days. Citius Oncology is currently does not generate positive expected returns and assumes 6.5251% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than Citius, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Citius Oncology Target Price Odds to finish over Current Price
The tendency of Citius Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.11 | 90 days | 1.11 | about 71.31 |
Based on a normal probability distribution, the odds of Citius Oncology to move above the current price in 90 days from now is about 71.31 (This Citius Oncology probability density function shows the probability of Citius Stock to fall within a particular range of prices over 90 days) .
Citius Oncology Price Density |
| Price |
Predictive Modules for Citius Oncology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Citius Oncology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Citius Oncology Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Citius Oncology is not an exception. The market had few large corrections towards the Citius Oncology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Citius Oncology, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Citius Oncology within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.55 | |
β | Beta against Dow Jones | 0.59 | |
σ | Overall volatility | 0.16 | |
Ir | Information ratio | -0.09 |
Citius Oncology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Citius Oncology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Citius Oncology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Citius Oncology generated a negative expected return over the last 90 days | |
| Citius Oncology has high historical volatility and very poor performance | |
| Citius Oncology may become a speculative penny stock | |
| Net Loss for the year was (24.76 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Citius Oncology generates negative cash flow from operations | |
| Citius Oncology has a frail financial position based on the latest SEC disclosures | |
| About 84.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: CEO Moves Why is Citius Oncology Inc stock going down - 2025 Trading Recap Smart Investment Allocation Insights - baoquankhu1.vn |
Citius Oncology Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Citius Stock often depends not only on the future outlook of the current and potential Citius Oncology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Citius Oncology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 73.3 M | |
| Cash And Short Term Investments | 3.9 M |
Citius Oncology Fundamentals Growth
Citius Stock prices reflect investors' perceptions of the future prospects and financial health of Citius Oncology, and Citius Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Citius Stock performance.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.16 | ||||
| Current Valuation | 102.27 M | ||||
| Shares Outstanding | 88.28 M | ||||
| Price To Book | 2.28 X | ||||
| EBITDA | (23.49 M) | ||||
| Net Income | (24.76 M) | ||||
| Total Debt | 3.8 M | ||||
| Book Value Per Share | 0.54 X | ||||
| Cash Flow From Operations | (5.49 M) | ||||
| Earnings Per Share | (0.34) X | ||||
| Market Capitalization | 97.99 M | ||||
| Total Asset | 100.94 M | ||||
| Retained Earnings | (64.04 M) | ||||
| Working Capital | (21.95 M) | ||||
About Citius Oncology Performance
Assessing Citius Oncology's fundamental ratios provides investors with valuable insights into Citius Oncology's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Citius Oncology is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.81) | (0.85) | |
| Return On Capital Employed | (0.53) | (0.55) | |
| Return On Assets | (0.28) | (0.30) | |
| Return On Equity | (0.63) | (0.67) |
Things to note about Citius Oncology performance evaluation
Checking the ongoing alerts about Citius Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Citius Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Citius Oncology generated a negative expected return over the last 90 days | |
| Citius Oncology has high historical volatility and very poor performance | |
| Citius Oncology may become a speculative penny stock | |
| Net Loss for the year was (24.76 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Citius Oncology generates negative cash flow from operations | |
| Citius Oncology has a frail financial position based on the latest SEC disclosures | |
| About 84.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: CEO Moves Why is Citius Oncology Inc stock going down - 2025 Trading Recap Smart Investment Allocation Insights - baoquankhu1.vn |
- Analyzing Citius Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Citius Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Citius Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Citius Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Citius Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Citius Oncology's stock. These opinions can provide insight into Citius Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Citius Stock Analysis
When running Citius Oncology's price analysis, check to measure Citius Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology is operating at the current time. Most of Citius Oncology's value examination focuses on studying past and present price action to predict the probability of Citius Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology's price. Additionally, you may evaluate how the addition of Citius Oncology to your portfolios can decrease your overall portfolio volatility.